Cryoport, Inc. is a temperature-controlled supply chain specialist for the life sciences, built around the movement and stewardship of sensitive biological materials. Founded in 1999, the company evolved from a niche cryogenic-shipping provider into an integrated platform, accelerated by its October 2020 acquisitions of CRYOPDP (specialty life-science logistics) and MVE Biological Solutions (cryogenic freezers and vacuum-insulated systems). These steps created a family of businesses spanning logistics execution, engineered containers, and cold-storage equipment under one umbrella.
Its core work supports clinical and commercial programs—especially in cell and gene therapy—through end-to-end temperature-controlled services. Offerings include cryogenic and deep-frozen shipping systems with continuous monitoring, specialty couriers and premium logistics, GMP biostorage, packaging and labeling, kit production, and regulated sample management. The aim is to protect product integrity “one patient, one therapy, one product at a time” while giving sponsors a single, risk-mitigating supply-chain partner from collection through final delivery.
The platform is supported by a global footprint of logistics hubs and BioServices facilities positioned near major R&D and manufacturing centers. Cryoport lists logistics sites in Irvine, Amsterdam, Stevenage, Sydney, and Tokyo, complemented by U.S. Global Supply Chain Centers in Morris Plains, New Jersey, and Houston, Texas, and European BioServices operations in Clermont-Ferrand, France; the network continues to expand, including a 2025 facility near Paris Charles de Gaulle Airport. Together these locations enable regional staging, compliant storage, and rapid, monitored movements across continents.
Across press materials and industry profiles, Cryoport is frequently characterized as a leading cold-chain partner for advanced therapeutics, serving biopharma, animal health, and reproductive medicine while prioritizing the complex needs of cell and gene therapy. Strategic collaborations—such as partnerships with Syneos Health, SK pharmteco, and Minaris Regenerative Medicine—reflect its role alongside contract manufacturers and clinical service providers to streamline development and commercialization. Earlier features highlighted the company’s contribution to delivering next-generation immunotherapies, underscoring the operational discipline required for cryogenic logistics at scale.